Receipti

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

tion of:

Stewart D. Lyman et al.,

Attorney Docket No.: 2813-L

Serial No.:

08/994,468

Group Art Unit: 1615

Filed:

December 19, 1997

Examiner:

Unknown

For:

MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING

HEMATOPOIETIC CELLS

REQUEST TO CORRECT FILING RECEIPT

Application Processing Division's Customer Correction Division Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

Applicants enclose a copy of the Official Filing Receipt that was received from the Patent and Trademark Office. The Filing Receipt contains incorrect information regarding the priority applications. The Continuing Data as claimed by applicants should read as follows:

"This application is a continuation of application Serial No. 08/444,627 filed May 19, 1995, which is a divisional of application Serial No. 08/243,545 filed May 11, 1994, now allowed and issued as U.S. Patent No. 5,554,512, which is a continuation-in-part of application Serial No. 08/209,502 filed March 7, 1994, now abandoned, which is a continuation-in-part of application Serial No. 08/162,407 filed December 3, 1993, now abandoned, which is a continuation-in-part of application Serial No. 08/111,758 filed August 25, 1993, which is a continuation-in-part of application Serial No. 08/106,463 filed August 12, 1993 which is a continuation-inpart of application Serial No. 08/068,394 filed May 24, 1993, now abandoned.

The invention title is incorrect on the Official Filing Receipt, with the misspelling of the word hematopoietic and should read as follows: "MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING HEMATOPOIETIC CELLS."

Applicants therefore request the aforementioned corrections be made and a new Filing Receipt issued.

Respectfully submitted,

ephen L. Malaska Attorney for Applicant

Reg. No. 32,655

Immunex Corporation Law Department 51 University Street Seattle, WA 98101

Telephone: (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Application Processing Division's Customer Correction Division, Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.







UNITED STATES L_ARTMENT OF COMMERCE Patent and Trademark Office ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
08/994,468	12/19/97	1615	\$1,200.00	2813-L	0	8	8

LAW DEPARTMENT
IMMUNEX CORPORATION
51 UNIVERSITY STREET
SEATTLE WA 98101

Receipt is acknowledged of this nonprevisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

STEWART D. LYMAN, SEATTLE, WA; M. PATRICIA BECKMANN, POULSBO, WA.

FOREIGN FILING LICENSE GRANTED 03/31/98
TITLE
MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING HEMATOPHOIETIC CELLS

PRELIMINARY CLASS: 435

TECH CENTER 1600/ 2300